ICP-490

Small molecule

BBeijing InnoCare Pharma Tech Co., Ltd.

ICP-490 is one of 53 small molecule programs targeting Lymphoma. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Multiple MyelomaActive, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

Multiple MyelomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Oncaspar

SServier

Preclinical

15 3

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 4

Nuvigil

NNuvo Research GmbH

Preclinical

1 5

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—6

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—7

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

PEG-Intron

1 9

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

2 10

R-CHOP

IIncyte Biosciences Japan GK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1/2Not yet recruiting

Lymphoma

NCT06845241

Clinical

Trials by Indication[1]

Multiple Myeloma1 trial

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma

Recruiting·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 1/2·NCT05719701·80 enrolled

Lymphoma1 trial

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Not yet recruiting·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 1/2·NCT06845241·68 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ICP-490. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ICP-490 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ICP-490. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing InnoCare Pharma Tech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: BBeijing InnoCare Pharma Tech Co., Ltd.

ICP-490

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Multiple Myeloma1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News